Introduction
============

Several decades ago, lung cancer emerged as the most common cancer worldwide \[[@b1-kjtcvs-52-342]\]. In developed countries, the incidence of lung cancer and deaths from lung cancer have been steadily declining as a result of the implementation of comprehensive tobacco control programs to reduce tobacco use. However, lung cancer is still the leading cause of cancer-related death worldwide because of the high fatality associated with the disease \[[@b1-kjtcvs-52-342]\].

The decline in the prevalence of tobacco smoking has been accompanied by notable changes in the histologic subtypes of lung cancer. Squamous cell carcinoma was previously the most prevalent histologic subtype, but it has been gradually replaced by adenocarcinoma since the mid-1970s \[[@b2-kjtcvs-52-342]\]. In 2011, a new classification of adenocarcinoma was proposed by the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society (IASLC/ATS/ERS). In this classification, 5 distinct subtypes of invasive adenocarcinoma were defined: the lepidic (LEP) subtype (low grade, favorable prognosis), the acinar (ACN) and papillary (PAP) subtypes (intermediate grade and prognosis), and the solid (SOL) and micropapillary (MIP) subtypes (high grade, poor prognosis). The associations between the predominant subtypes and prognoses have been validated by several studies \[[@b3-kjtcvs-52-342]\].

Smoking is a well-established causative factor of all types of lung cancer. In addition to describing the link between smoking and carcinogenesis, previous studies showed that among individuals with non-small cell lung cancer, those with a history of smoking had poorer survival than never-smokers \[[@b4-kjtcvs-52-342]\]. Smoking is most strongly linked with squamous cell carcinoma and small cell lung cancer, while adenocarcinoma is the predominant type of lung cancer in lifelong never-smokers \[[@b5-kjtcvs-52-342]\]. Nevertheless, a small number of influential studies reported that smoking had a prognostic impact on adenocarcinoma, and some authors proposed a relationship between smoking and the histologic subtypes of adenocarcinoma as a mechanism to explain the poorer outcomes of adenocarcinoma patients with a history of smoking \[[@b6-kjtcvs-52-342]\]. However, those studies used the previous classification (bronchioloalveolar carcinoma) or did not include all 5 major subtypes of invasive adenocarcinoma, having been performed and reported before the new IASLC/ATS/ERS classification.

In the present study, we reassessed the predominant histologic subtypes according to the new IASLC/ATS/ERS classification and investigated (1) the prognostic impact of smoking and (2) the association between smoking status and histologic subtypes in patients with completely resected adenocarcinoma.

Methods
=======

1) Patients and eligibility criteria
------------------------------------

We searched the thoracic surgical database of Dong-A University Hospital and identified 261 patients who underwent surgical resection with curative intent for pathologic stage I--III adenocarcinomas from January 2004 to July 2015. The standard surgical treatment was lobectomy with hilar and mediastinal lymph node dissection. However, in 20 cases, segmentectomy was performed as an optional strategy when a peripheral tumor (less than 2 cm and without nodal involvement) was resected completely with appropriate surgical margins. If any lymph node involvement was detected in frozen section biopsy specimens, the procedure was converted to lobectomy.

The following exclusion criteria were applied: (I) N3 or M1 disease, (II) residual tumor or involved resection margin, (III) preinvasive lesions including atypical adenomatous hyperplasia and adenocarcinoma *in situ* (AIS), (IV) neoadjuvant chemotherapy or radiation therapy, (V) sublobar resection due to poor lung function, (VI) death from early complications within 30 days of the operation. The records of the 233 eligible patients with pathologic T1-4N0-2M0 adenocarcinomas were evaluated. The institutional review board at Dong-A University Hospital approved this retrospective study with a waiver of informed consent, because the patients' personal data had been secured (IRB No., DAUHIRB-19-177).

2) Clinicopathologic information
--------------------------------

We obtained clinicopathologic information from the patients' medical records. Cigarette smoking status was based on self-reported smoking behavior, using values obtained during clinical encounters that were closest in time to the date of the lung cancer operation. The amount of smoking was quantified in pack-years (PY), which were calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the patient had smoked. Patients were classified into an ever-smoking group and a non-smoking group based on their history. The ever-smoking group included both current smokers and ex-smokers. A non-smoker was defined as someone who has not smoked in her lifetime. A current smoker was a patient who had smoked and continued to smoke until the time of diagnosis. An ex-smoker was defined as someone who had smoked at any point in his or her life but had not smoked in the last 28 days.

Charlson comorbidity index (CCI) scores were used to estimate the severity of comorbidities. As all patients had a malignancy, weights were not assigned to the cancer diagnosis. Age was also not included in the score because it was used as an independent variable.

The disease stages of all resected tumors were reassessed according to the eighth edition of the TNM classification system. Following the 2015 World Health Organization classification of lung tumors, pathologists reviewed all of the tumor slides using comprehensive histologic subtyping to make a semi-quantitative estimate of the different histologic patterns present in 5% increments. The predominant subtype was defined as the pattern involving the largest proportion of the tumor, and the tumors were categorized into 3 subgroups based on the grading system: (I) LEP-predominant, (II) ACN or PAP (ACN/PAP)-predominant, or (III) SOL or MIP (SOL/MIP)-predominant.

All patients were followed-up through routine office visits or by telephone contacts. For the first 2 years, they received physical examinations, plain chest X-rays, and chest computed tomography scans at 6-month intervals. Thereafter, they were examined every 6 months or annually. Overall survival (OS) was calculated from the date of initial surgery to the date of death from any cause. Recurrence-free survival (RFS) was defined as the time interval between surgery and clinical or pathological recurrence. Patients without death or recurrence were censored at the end of the follow-up period for OS or RFS, respectively.

The clinicopathologic data included age, sex, smoking status (never or ever), CCI (0--1 or ≥2), carcinoembryonic antigen (CEA) level (cutoff at the upper limit of normal, 5 ng/mL), forced expiratory volume in 1 second (FEV1; ≥70% or \<70%), procedure (lobectomy or segmentectomy), adjuvant treatment (no or yes), pathologic tumor size (≤3 cm or \>3 cm), tumor laterality (right or left), lobar location (upper/middle or lower), nodal status (N0 or N1--2), visceral pleural invasion (VPI; absent or present), lymphovascular invasion (LVI; absent or present), and predominant subtype (LEP, ACN/PAP, or SOL/MIP).

3) Statistical analysis
-----------------------

Differences in variables were evaluated using the chi-square test, Student t-test, and linear-by-linear associations. Survival probability was estimated from Kaplan-Meier curves, and the log-rank test was used to assess the significance of differences. Univariate and multivariate analyses were performed using Cox proportional hazards models to identify independent factors associated with OS or RFS. Clinical predictors for SOL/MIP-predominant tumors were identified by logistic regression analysis. Multivariate analyses were performed with variables demonstrating a p-value \< 0.2 in the univariate analysis. A 2-sided p-value \<0.05 was considered to indicate statistical significance. All statistical analyses were conducted using IBM SPSS Statistics ver. 20.0 (IBM Corp., Armonk, NY, USA).

Results
=======

1) Patient characteristics according to smoking status and overall survival and recurrence-free survival analyses
-----------------------------------------------------------------------------------------------------------------

The median follow-up period was 47 months (range, 3--158 months). During follow-up, 75 deaths (32.2%) occurred, and 84 patients (36.1%) experienced recurrence. Among the 233 patients, 119 (51.1%) were non-smokers and 114 (48.9%) were ever-smokers. Of the 114 ever-smokers, 61 were current smokers and 53 were ex-smokers. The clinicopathologic characteristics according to smoking status are presented in [Table 1](#t1-kjtcvs-52-342){ref-type="table"}. The majority (84.2%) of the ever-smokers were male (p=0.000), and ever-smoker status was significantly associated with a high CEA level (p=0.008), low FEV1 (p=0.038), VPI (p=0.004), and the SOL/MIP-predominant subtype (p=0.001). A significant difference was found in the OS probability between non-smokers and ever-smokers (p=0.003); their 5-year OS rates were 80.8% and 65.1%, respectively. Although the difference in their RFS probabilities was not significant (p=0.162), there was a trend for shorter RFS in ever-smokers than in non-smokers.

The univariate analyses of OS identified sex, smoking status, CEA, FEV1, tumor size, nodal status, VPI, LVI, and predominant subtype as significant prognostic factors. The univariate analyses of RFS identified CEA, tumor size, nodal status, VPI, LVI, and predominant subtype as significantly associated with shorter RFS. In the multivariate analyses, the presence of LVI and predominant subtypes remained statistically significant as independent prognostic factors of both OS and RFS ([Table 2](#t2-kjtcvs-52-342){ref-type="table"}).

2) Patient characteristics according to histologic subtypes and analysis of clinical predictors of solid/micropapillary-predominant adenocarcinoma
--------------------------------------------------------------------------------------------------------------------------------------------------

The distribution of predominant subtypes demonstrated a significant difference according to smoking status ([Table 1](#t1-kjtcvs-52-342){ref-type="table"}). Among the 3 subtypes, SOL/MIP- predominant tumors had the poorest outcomes for both survival (p=0.000) and recurrence (p=0.001). Therefore, we hypothesized a close correlation between smoking status and SOL/MIP-predominant adenocarcinoma. In the subsequent analysis of the clinicopathologic data based on SOL/MIP predominance ([Table 3](#t3-kjtcvs-52-342){ref-type="table"}), the presence of a SOL/MIP-predominant tumor was associated with male sex (p=0.005), smoking history (p=0.003), higher pathologic stage (p=0.002), a tumor size larger than 3 cm (p=0.014), and the presence of VPI (p=0.038). Univariate and multivariate analyses excluding pathologic variables identified smoking history (p=0.005) and tumor size larger than 3 cm (p=0.025) as independent clinical predictors of SOL/MIP predominance ([Table 4](#t4-kjtcvs-52-342){ref-type="table"}).

3) Associations between smoking quantity and histologic subtypes
----------------------------------------------------------------

We examined the associations between smoking status and all histologic subtypes, including SOL/MIP- predominant tumors. [Fig. 1A](#f1-kjtcvs-52-342){ref-type="fig"} shows the proportion of smokers among patients according to the predominant subtype. The percentage of smokers was higher in the higher-grade group (p=0.001). The proportion of smokers was 36.5% (19 of 52) among patients with LEP-predominant tumors. In contrast, the proportion of smokers among patients with SOL/MIP- predominant tumors was 70.7% (29 of 41).

Among the 114 smokers, the smoking quantity of all but 1 was identified. In ever-smokers, the median value of smoking quantity was 30 PY (range, 0.2--144.5 PY). When the distribution of predominant subtypes was analyzed based on a threshold of 30 PY ([Fig. 1B](#f1-kjtcvs-52-342){ref-type="fig"}), the proportion of LEP-predominant tumors was significantly higher in patients with a smoking history of 30 PY or less. Conversely, the proportion of SOL/MIP-predominant tumors was higher in patients with over 30 PY (p=0.023).

Smoking quantity was also compared across the different subtypes ([Fig. 2](#f2-kjtcvs-52-342){ref-type="fig"}). Patients with higher-grade predominant tumors also had a greater smoking quantity in terms of PY. The 28 ever-smokers with SOL/MIP-predominant tumors (32.7±19.9 PY) tended to have smoked more than the 19 ever-smokers with LEP-predominant tumors (19.1±10.6 PY) (p=0.004). No significant difference in smoking quantity was found between the 36 ever-smokers with non-predominant SOL/MIP components (31.0±16.5 PY) and the 28 ever-smokers with predominant SOL/MIP components (32.7±19.9 PY) (p=0.718). However, a significant difference in smoking quantity was found when comparing groups defined by the presence of a SOL/MIP component (31.7±17.9 PY versus 23.7±17.2 PY), while ignoring predominance (p=0.026).

Discussion
==========

Similar to previous studies, patients with adenocarcinoma who had a history of smoking had a poorer prognosis in our study. Several clinical and epidemiological inferences may be drawn from this association. Because smoking is a well-known risk factor for postoperative complications, it is possible that complications may contribute in part to the unfavorable prognosis of patients with a history of smoking. However, our study eliminated this possibility by excluding patients who died from postoperative complications. Smoking is also associated with many other diseases, such as cardiovascular disease, pulmonary disease, diabetes, and infections. Although we conducted a multivariate analysis to offset the influence of comorbidities on survival, the adverse effect of smoking remained significant. Almost all patients stopped smoking after surgery; however, the cumulative effect of smoking may have led to death or recurrence by inducing second cancers or promoting the aforementioned chronic diseases during the follow-up period. In this and previous studies, the smokers were predominantly male. In the large retrospective study of Tseng et al. \[[@b7-kjtcvs-52-342]\], male sex was an independent poor prognostic factor for OS regardless of epidermal growth factor receptor (EGFR) mutation status.

The molecular and genomic characteristics of adenocarcinoma differ between patients who have never smoked and those with a history of smoking. Mutations in the p53 gene are present in all lung cancers, whereas mutations in the *KRAS* gene are predominantly present in adenocarcinomas in individuals who have a history of smoking \[[@b8-kjtcvs-52-342]\]. *KRAS* mutations generally mark a poor prognosis and are associated with intrinsic EGFR tyrosine kinase inhibitor (TKI) resistance. Never-smokers have demonstrated better therapeutic responses to EGFR TKIs, probably due to the higher occurrence of EGFR mutations in never-smokers \[[@b9-kjtcvs-52-342]\]. Several studies have proposed mechanisms of resistance to EGFR TKIs related to smoking. Smoking induces the activation of cytochrome CYP 1A1 \[[@b10-kjtcvs-52-342]\] and the release of reactive oxidative stress species, while promoting autophosphorylation \[[@b11-kjtcvs-52-342]\]. Smoking also involves the activation of Src, the inhibition of which restored TKI sensitivity \[[@b12-kjtcvs-52-342]\].

Several authors have reported a relationship between the predominant histologic subtype and prognosis in lung adenocarcinoma \[[@b4-kjtcvs-52-342]\]. While LEP-predominant invasive adenocarcinomas have a better prognosis, SOL/MIP-predominant tumors show a worse prognosis than the other 3 subtypes. In an effort to determine the underlying biology, several research groups have correlated histologic subtypes with the mutational status of the tumors, but no specific or consistent correlation has been found between histologic subtypes and oncogenic driver mutations \[[@b13-kjtcvs-52-342]\]. In our study, SOL/MIP-predominant tumors were not significantly associated with CEA, LVI, or nodal metastasis, which have been identified as prognostic factors in previous studies. Nonetheless, these tumors were associated with poorer outcomes of survival and recurrence than tumors with other predominant subtypes.

Our study also demonstrated an association of a history of ever smoking with SOL/MIP-predominant tumors, which may provide a partial explanation for the poorer prognosis in the smokers. A few other retrospective studies have explored this association, but most of them did not include all 5 major subtypes because they were reported before the development of the 2015 World Health Organization classification. Nearly all of them reported a positive association between smoking and high-grade subtypes. However, the mechanisms underlying this association are not fully understood, and additional studies are necessary to clarify this issue. In the case-control study of Bracci at al. \[[@b14-kjtcvs-52-342]\], smoking status was positively associated with AIS risk, whereas the risk of AIS decreased with years since quitting smoking. In addition, patients with AIS were less likely to be ever-smokers or heavy smokers than those with other histologic subtypes. More recently, Lappi-Blanco et al. \[[@b15-kjtcvs-52-342]\] reported that an altered MUC1 expression pattern was frequently observed in SOL-predominant adenocarcinomas and was correlated with reduced overall survival and smoking history. Similarly, Rokutan-Kurata et al. \[[@b16-kjtcvs-52-342]\] found that MUC4-positive lung adenocarcinoma was correlated with male smokers, SOL subtype, HER2 expression, and a poorer prognosis.

Although several studies have reported encouraging results of sublobar resection for small, peripheral adenocarcinomas, sublobar resection may be less ideal for tumors with SOL/MIP components. Many studies identified that having non-predominant MIP/SOL components was a negative prognostic factor in patients who underwent even lobectomy \[[@b17-kjtcvs-52-342]\]. When treated with sublobar resection, peripheral adenocarcinoma ≤2 cm with an MIP component of 5% or greater showed a higher cumulative incidence of recurrence \[[@b18-kjtcvs-52-342]\]. Yeh et al. \[[@b19-kjtcvs-52-342]\] reported that the presence of a SOL component was also found to correlate with locoregional recurrence, and that distant recurrence was correlated with the predominant histologic subtype and the MIP component. Furthermore, occult lymph node metastasis was associated with non-predominant SOL/MIP components \[[@b20-kjtcvs-52-342]\].

These studies raise the question of how to recognize SOL/MIP components preoperatively. Cha et al. \[[@b21-kjtcvs-52-342]\] tried to predict the presence of SOL/MIP components by using radiological parameters including tumor size \>2.5 cm, pure solidity, and maximum standardized uptake value ≥7. Similarly, our results demonstrated that smoking history and tumor size \>3 cm were independent predictors of SOL/MIP-predominant tumors. In addition, a greater smoking quantity was associated with SOL/MIP predominance. However, the difference in smoking quantity was not significant between the tumors with SOL/MIP-predominant components and those with non-predominant SOL/MIP components. In our opinion, smoking history---and more specifically, greater smoking quantity---seems promising for use in a predictive model, and further studies with larger cohorts are needed.

Our study is limited by the relatively small sample size and the retrospective, single-institution study design. Additionally, our cohort included 20 cases of segmentectomy, although none of them experienced death or recurrence. Because smoking status and quantity were assessed based on patients' reports, without biochemical methods, those data might be biased. Although smoking status during the follow-up period was not taken into consideration in our analysis, almost all patients quit after surgery. We also did not assess exposure to secondhand smoke, air pollution, or occupational carcinogens due to the difficulty of objective quantification. Another limitation was the imbalance in the proportion of males and females in the never-smoker and ever-smoker groups.

In conclusion, our results show that smoking was closely associated with SOL/MIP-predominance in lung adenocarcinoma. A larger smoking quantity was associated with the presence of a SOL/MIP component, but may not be related to the predominant subtype. These associations between smoking and histologic subtype suggest a possible mechanism underlying the poorer prognosis of patients with adenocarcinoma and history of smoking.
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###### 

Clinicopathologic characteristics of patients according to smoking status

  Characteristic                             Total (n=233)   Never-smoker (n=119)   Ever-smoker (n=114)   p-value
  ------------------------------------------ --------------- ---------------------- --------------------- ---------
  Sex                                                                                                     0.000
   Male                                      118 (50.6)      22 (18.5)              96 (84.2)             
   Female                                    115 (49.4)      97 (81.5)              18 (15.8)             
  Age (yr)                                   63.6±9.4        63.8±8.9               63.4±9.8              0.749
  Charlson comorbidity index                                                                              0.861
   0--1                                      181 (77.7)      93 (78.2)              88 (77.2)             
   ≥2                                        52 (22.3)       26 (21.8)              26 (22.8)             
  Carcinoembryonic antigen (ng/mL)                                                                        0.008
   ≤5                                        138 (72.3)      74 (81.3)              64 (64.0)             
   \>5                                       53 (27.7)       17 (18.7)              36 (36.0)             
   Unknown                                   42                                                           
  Forced expiratory volume in 1 second (%)                                                                0.038
   ≥70                                       220 (94.4)      116 (97.5)             104 (91.2)            
   \<70                                      13 (5.6)        3 (2.5)                10 (8.8)              
  Pathologic stage                                                                                        0.139
   1                                         127 (54.5)      72 (60.5)              55 (48.2)             
   2                                         55 (23.6)       23 (19.3)              32 (28.1)             
   3                                         51 (21.9)       24 (20.2)              27 (23.7)             
  Procedure                                                                                               0.535
   Lobectomy                                 214 (91.8)      108 (90.8)             106 (93.0)            
   Segmentectomy                             20 (8.2)        11 (9.2)               8 (7.0)               
  Adjuvant treatment                                                                                      0.902
   No                                        144 (61.8)      74 (62.2)              70 (61.4)             
   Yes                                       89 (38.2)       45 (37.8)              44 (38.6)             
  Tumor size (cm)                                                                                         0.612
   ≤3                                        157 (67.4)      80 (67.2)              73 (64.0)             
   \>3                                       76 (32.6)       39 (32.8)              41 (36.0)             
  Tumor laterality                                                                                        0.498
   Right                                     142 (60.9)      70 (58.8)              72 (63.2)             
   Left                                      91 (39.1)       49 (41.2)              42 (36.8)             
  Lobar location                                                                                          0.492
   Upper/middle                              144 (61.8)      71 (59.7)              73 (64.0)             
   Lower                                     89 (38.2)       48 (40.3)              41 (36.0)             
  Nodal status                                                                                            0.608
   N0                                        153 (65.7)      80 (67.2)              73 (64.0)             
   N1--2                                     80 (34.3)       39 (32.8)              41 (36.0)             
  Visceral pleural invasion                                                                               0.004
   Absent                                    160 (68.7)      92 (77.3)              68 (59.6)             
   Present                                   73 (31.3)       27 (22.7)              46 (40.4)             
  Lymphovascular invasion                                                                                 0.620
   Absent                                    169 (72.5)      88 (73.9)              81 (71.1)             
   Present                                   64 (27.5)       31 (26.1)              33 (28.9)             
  Predominant subtype                                                                                     0.001
   Lepidic                                   52 (24.6)       33 (31.1)              19 (18.1)             
   Acinar/papillary                          72/46 (55.9)    61 (57.5)              57 (54.3)             
   Solid/micropapillary                      38/3 (19.4)     12 (11.3)              29 (27.6)             
   Variant                                   22                                                           

Values are presented as number (%) or mean±standard deviation.

###### 

Multivariate analyses of overall survival and recurrence-free survival

  Variable                                   Overall survival       Recurrence-free survival                          
  ------------------------------------------ ---------------------- -------------------------- ---------------------- -------
  Sex                                                                                          Not included           
                                                                                                                      
   Male                                      1.010 (0.434--2.353)   0.981                                             
                                                                                                                      
   Female                                    1                                                                        
                                                                                                                      
  Age                                        1.025 (0.993--1.058)   0.123                      Not included           
                                                                                                                      
  Smoking                                                                                                             
                                                                                                                      
   Never                                     1                                                 1                      
                                                                                                                      
   Ever/current                              2.332 (1.246--4.365)   0.008                      1.580 (0.915--2.728)   0.101
                                                                                                                      
  Carcinoembryonic antigen (ng/mL)                                                                                    
                                                                                                                      
   ≤5                                        1                                                 1                      
                                                                                                                      
   \>5                                       1.399 (0.776--2.525)   0.264                      1.439 (0.822--2.518)   0.202
                                                                                                                      
  Forced expiratory volume in 1 second (%)                                                     Not included           
                                                                                                                      
   ≥70                                       1                                                                        
                                                                                                                      
   \<70                                      3.530 (1.456--8.561)   0.005                                             
                                                                                                                      
  Procedure                                  Not included                                                             
                                                                                                                      
   Lobectomy                                                                                   1                      
                                                                                                                      
   Segmentectomy                                                                               0.224 (0.030--1.659)   0.143
                                                                                                                      
  Adjuvant treatment                                                                                                  
                                                                                                                      
   No                                        1                                                 1                      
                                                                                                                      
   Yes                                       1.277 (0.693--2.353)   0.433                      1.085 (0.544--2.166)   0.816
                                                                                                                      
  Tumor size (cm)                                                                                                     
                                                                                                                      
   ≤3                                        1                                                 1                      
                                                                                                                      
   \>3                                       1.216 (0.668--2.215)   0.522                      0.798 (0.444--1.434)   0.451
                                                                                                                      
  Tumor laterality                           Not included                                                             
                                                                                                                      
   Right                                                                                       1                      
                                                                                                                      
   Left                                                                                        0.983 (0.564--1.714)   0.951
                                                                                                                      
  Nodal status                                                                                                        
                                                                                                                      
   N0                                        1                                                 1                      
                                                                                                                      
   N1--2                                     0.793 (0.404--1.557)   0.500                      1.424 (0.797--2.544)   0.233
                                                                                                                      
  Visceral pleural invasion                                                                                           
                                                                                                                      
   Absent                                    1                                                 1                      
                                                                                                                      
   Present                                   0.705 (0.391--1.269)   0.244                      1.300 (0.732--2.308)   0.371
                                                                                                                      
  Lymphovascular invasion                                                                                             
                                                                                                                      
   Absent                                    1                                                 1                      
                                                                                                                      
   Present                                   2.727 (1.536--4.843)   0.001                      2.033 (1.179--3.505)   0.011
                                                                                                                      
  Predominant subtype                                                                                                 
                                                                                                                      
   Lepidic                                   1                      0.003                      1                      0.036
                                                                                                                      
   Acinar/papillary                          1.479 (0.603--3.631)   0.393                      1.165 (0.542--2.505)   0.696
                                                                                                                      
   Solid/micropapillary                      3.812 (1.473--9.863)   0.006                      2.438 (1.049--5.667)   0.038

Multivariate analyses were performed with variables demonstrating a p-value ≤0.2 in univariate analyses. HR, hazard ratio; CI, confidence interval.

###### 

Clinicopathologic characteristics according to the predominant subtype

  Variable                                   Other subtype-predominant tumors (n=170)   Solid/micropapillary-predominant tumors (n=41)   p-value
  ------------------------------------------ ------------------------------------------ ------------------------------------------------ ---------
  Sex                                                                                                                                    0.005
   Male                                      79 (46.5)                                  29 (70.7)                                        
   Female                                    91 (53.5)                                  12 (29.3)                                        
  Age (yr)                                   63.2±9.1                                   65.4±10.0                                        0.178
  Smoking                                                                                                                                0.003
   Never                                     94 (55.3)                                  12 (29.3)                                        
   Ever/current                              76 (44.7)                                  29 (70.7)                                        
  Charlson comorbidity index                                                                                                             0.582
   0--1                                      130 (76.5)                                 33 (80.5)                                        
   ≥2                                        40 (23.5)                                  8 (19.5)                                         
  Carcinoembryonic antigen (ng/mL)                                                                                                       0.553
   ≤5                                        103 (73.6)                                 24 (68.6)                                        
   \>5                                       37 (26.4)                                  11 (31.4)                                        
  Forced expiratory volume in 1 second (%)                                                                                               0.720
   ≥70                                       160 (94.1)                                 38 (92.7)                                        
   \<70                                      10 (5.9)                                   3 (7.3)                                          
  Pathologic stage                                                                                                                       0.002
   1                                         103 (60.6)                                 15 (36.6)                                        
   2                                         37 (21.8)                                  11 (26.8)                                        
   3                                         30 (17.6)                                  15 (36.6)                                        
  Procedure                                                                                                                              0.304
   Lobectomy                                 153 (90.0)                                 39 (95.1)                                        
   Segmentectomy                             17 (10.0)                                  2 (4.9)                                          
  Adjuvant treatment                                                                                                                     0.243
   No                                        108 (63.5)                                 22 (53.7)                                        
   Yes                                       62 (36.5)                                  19 (46.3)                                        
  Tumor size (cm)                                                                                                                        
   ≤3                                        128 (75.3)                                 23 (56.1)                                        
   \>3                                       42 (24.7)                                  18 (43.9)                                        0.014
  Tumor laterality                                                                                                                       0.877
   Right                                     110 (64.7)                                 26 (63.4)                                        
   Left                                      60 (35.3)                                  15 (36.6)                                        
  Lobar location                                                                                                                         0.461
   Upper/middle                              110 (64.7)                                 24 (58.5)                                        
   Lower                                     60 (35.3)                                  17 (41.5)                                        
  Nodal status                                                                                                                           0.055
   N0                                        118 (69.4)                                 22 (53.7)                                        
   N1--2                                     52 (30.6)                                  19 (46.3)                                        
  Visceral pleural invasion                                                                                                              0.038
   Absent                                    120 (70.6)                                 22 (53.7)                                        
   Present                                   50 (29.4)                                  19 (46.3)                                        
  Lymphovascular invasion                                                                                                                0.799
   Absent                                    121 (71.2)                                 30 (73.2)                                        
   Present                                   49 (28.8)                                  11 (26.8)                                        

Values are presented as number (%) or mean±standard deviation.

###### 

Univariate and multivariate analyses of clinical predictors for the predominance of a solid or micropapillary subtype

  Variable                                   Univariate analysis    Multivariate analysis                          
  ------------------------------------------ ---------------------- ----------------------- ---------------------- -------
  Sex                                                                                                              
                                                                                                                   
   Male                                      2.784 (1.332--5.818)   0.006                   1.748 (0.663--4.612)   0.259
                                                                                                                   
   Female                                    1                                              1                      
                                                                                                                   
  Age                                        1.027 (0.988--1.067)   0.178                   1.023 (0.984--1.064)   0.256
                                                                                                                   
  Smoking                                                                                                          
                                                                                                                   
   Never                                     1                                              1                      
                                                                                                                   
   Ever/current                              2.989 (1.430--6.250)   0.004                   2.908 (1.379--6.131)   0.005
                                                                                                                   
  Charlson comorbidity index                                                                                       
                                                                                                                   
   0--1                                      1                                                                     
                                                                                                                   
   ≥2                                        0.788 (0.337--1.843)   0.582                                          
                                                                                                                   
  Carcinoembryonic antigen (ng/mL)                                                                                 
                                                                                                                   
   ≤5                                        1                                                                     
                                                                                                                   
   \>5                                       1.276 (0.570--2.858)   0.554                                          
                                                                                                                   
  Forced expiratory volume in 1 second (%)                                                                         
                                                                                                                   
   ≥70                                       1                                                                     
                                                                                                                   
   \<70                                      1.263 (0.331--4.813)   0.409                                          
                                                                                                                   
  Procedure                                                                                                        
                                                                                                                   
   Lobectomy                                 1                                                                     
                                                                                                                   
   Segmentectomy                             0.462 (0.102--2.082)   0.732                                          
                                                                                                                   
  Tumor size (cm)                                                                                                  
                                                                                                                   
   ≤3                                        1                                              1                      
                                                                                                                   
   \>3                                       2.385 (1.174--4.844)   0.016                   2.296 (1.112--4.742)   0.025
                                                                                                                   
  Tumor laterality                                                                                                 
                                                                                                                   
   Right                                     1                                                                     
                                                                                                                   
   Left                                      1.058 (0.520--2.149)   0.877                                          
                                                                                                                   
  Lobar location                                                                                                   
                                                                                                                   
   Upper/middle                              1                                                                     
                                                                                                                   
   Lower                                     1.058 (0.520--2.149)   0.877                                          

Multivariate analyses were performed with variables demonstrating a p-value ≤0.2 in univariate analyses. OR, odds ratio; CI, confidence interval.
